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phenotype and was highest for patients with a positive fam-
ily history of hearing loss or when the loss was congenital 
and symmetric. The spectrum of implicated genes showed 
wide ethnic variability. These findings support the more 
efficient utilization of medical resources through the devel-
opment of evidence-based algorithms for the diagnosis of 
hearing loss.
Introduction
Hearing loss is the most common sensory deficit in 
humans. It is diagnosed in 1 in 500 newborns and affects 
half of all octogenarians (Fortnum et al. 2001; Morton and 
Nance 2006). Although causality is multifactorial, in devel-
oped countries, a large fraction of hearing loss is genetic 
and non-syndromic, i.e., not associated with other pheno-
types (Marazita et al. 1993). Non-syndromic hearing loss 
(NSHL) mimics are syndromic forms of hearing loss that 
present as NSHL early in life with syndromic features 
developing later. Type 1 Usher syndrome, for example, is 
an NSHL mimic presenting as congenital profound hearing 
loss with delayed motor milestones. The associated pro-
gressive vision loss begins in late childhood (Smith et al. 
1994).
Genetic diagnosis of NSHL and NSHL mimics is valua-
ble. It provides prognostic information on possible progres-
sion of hearing loss, permits meaningful genetic counseling, 
and impacts treatment decisions (Kimberling et al. 2010). 
A positive diagnosis also saves healthcare dollars by direct-
ing the clinical evaluation and obviating unnecessary testing 
such as the routine use of imaging. The challenge, however, 
is in providing comprehensive genetic testing. Hearing loss 
is extremely heterogeneous, with over 90 genes causally 
implicated in NSHL (Van Camp and Smith 2015). Although 
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historically this heterogeneity restricted genetic testing to 
just a few genes (Hilgert et al. 2009), the advent of targeted 
genomic enrichment and massively parallel sequencing 
(TGE + MPS) has revolutionized the clinical care of the 
patient with hearing loss by making comprehensive genetic 
testing possible (Shearer and Smith 2015).
TGE + MPS have been used in several small cohorts 
with positive diagnostic rates that range from 10 to 83 % 
[reviewed in (Shearer and Smith 2015)]. This variability 
reflects selection bias (i.e., including only a select ethnicity 
or only patients with a positive family history for hearing 
loss), platform bias (i.e., including only a limited number of 
genes), and analytic bias (i.e., neglecting to consider copy 
number variations in the analysis) (Hoppman et al. 2013; Ji 
et al. 2014; Shearer et al. 2013, 2014b). Herein, we report 
the analysis of the largest patient cohort to date that has 
undergone comprehensive clinical genetic testing for hear-
ing loss. Of the 1119 patients presenting for testing in our 
clinical diagnostic laboratory, we were able to diagnose a 
genetic cause of deafness in 440 persons (39 %). We show 
that the diagnostic rate reflects ethnicity and clinical pheno-
type, and ranges from 1 % in patients with unilateral hearing 
loss to 72 % in patients of Middle Eastern ethnicity. These 
results provide a foundation from which to make appropri-
ate recommendations for the use of comprehensive genetic 
testing in the evaluation of patients with hearing loss.
Materials and methods
Patients
Patients included in this study were sequentially referred to 
the Molecular Otolaryngology and Renal Research Labo-
ratories (MORL) for clinical genetic testing from Janu-
ary 2012 to September 2014. All genetic screenings were 
done on a custom-designed TGE + MPS panel called Oto-
SCOPE® (Shearer et al. 2010). Relatives of patients were 
not included in this analysis (each nuclear and/or extended 
family was represented by only the proband), but no exclu-
sions were otherwise made based upon age, age of onset, 
phenotype or previous testing. All available phenotype, 
family history, and ethnicity data were recorded. Abnor-
mal physical exam features were classified as described in 
Table S1. The Institutional Review Board of the University 
of Iowa approved this study, and the described research was 
performed in accordance with the Declaration of Helsinki.
Library preparation, sequencing and bioinformatics
TGE + MPS were completed on DNA prepared from 
whole blood using a Sciclone NGS workstation (Perki-
nElmer, Waltham, MA) for sample preparation. The testing 
platform was either OtoSCOPE® v4 (408 individuals) or v5 
(711 individuals) which targets 66 or 89 deafness-associ-
ated genes, respectively (Table S2) using custom-designed 
SureDesign capture technology (Agilent Technologies, 
Santa Clara, CA). Each platform included all known NSHL 
and NSHL mimic genes at the time of design (May 2011 
and November 2012, respectively). Samples were analyzed 
in pools of 48 samples sequenced on an Illumina HiSeq 
(Illumina, Inc., San Diego, CA, USA) flow cell using 100-
bp paired-end reads. If pre-determined quality control 
values were not met, the sample was rerun, as previously 
described (Shearer et al. 2014b).
Data were analyzed using a local installation of the 
open-source Galaxy software (Blankenberg et al. 2010; 
Goecks et al. 2010) and a combination of several other 
open-source tools, including read mapping with Burrows–
Wheeler Alignment (BWA) (Li and Durbin 2009), dupli-
cate removal with Picard, local re-alignment and variant 
calling with GATK Unified Genotyper (McKenna et al. 
2010), enrichment statistics with NGSRich (Frommolt 
et al. 2012), and variant reporting and annotation with cus-
tom-produced software. Copy number variant analysis was 
performed as described (Nord et al. 2011; Shearer et al. 
2014b).
Variant interpretation
On a patient-by-patient basis, all variants were discussed 
in the context of phenotypic data at a weekly interdiscipli-
nary Hearing Group Meeting that included clinicians, sci-
entists, geneticists, genetic counselors, and bioinformati-
cians. Each variant’s interpretation included consideration 
of quality/coverage depth (QD ≥ 5), minor allele frequency 
(MAF) from 1000 Genomes Project Database and the 
National Heart, Lung, and Blood Institute (NHLBI) Exome 
Sequencing Project Exome Variant Server [thresholds for 
recessive and dominant NSHL were <0.005 (excluding 
GJB2 variants) and <0.0005, respectively] (Shearer et al. 
2014a) conservation (GERP and PhyloP) and pathogenic-
ity prediction annotation (including PolyPhen2, SIFT, 
MutationTaster and LRT), and annotation within the Deaf-
ness Variation Database (deafnessvariationdatabase.org), 
an in-house curated, open-access database. Based upon the 
decision reached at Hearing Group Meeting, result letters 
were generated for all patients, reporting all variants with 
MAF <1 % to the ordering physician. In the case of posi-
tive results [variant(s) reported as ‘pathogenic’ or ‘likely 
pathogenic’ based on criteria defined by the American 
College of Medical Genetics and Genomics (ACMG) and 
further refined by the MORL for NSHL] (Richards et al. 
2015; Shearer et al. 2014a), clinical correlation and segre-
gation analysis were recommended. Positive results were 
confirmed via Sanger sequencing prior to reporting. The 
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majority of rare variants deemed unlikely to cause hearing 
loss and not previously reported to be pathogenic were cat-
egorized as Variants of Unknown Significance (VUSs).
Statistical analysis
All provided clinical and phenotypic data were recorded. Diag-
nostic rates were compared using the Fisher exact test (com-
paring a specified group to all other members of the cohort) or 
Chi-square test (comparing more than 2 groups), with p < 0.05 
considered significant. Data were compiled using Microsoft 
Excel and analyzed using Prism 6 (GraphPad).
Results
Patients
1119 unrelated patients were sequentially accrued during 
the study period. Relations were not included; otherwise, 
there were no exclusionary criteria. Patient demographics 
were binned into broad key categories: inheritance, onset, 
severity, laterality, physical exam and previous genetic test-























































































































































Fig. 1  Diagnostic rates are dependent on patient-specific clinical and 
phenotypic characteristics and are shown as the percentage of patients 
with the noted characteristic. Background shading separates catego-
ries. N for each characteristic is listed after the label. Dashed line 
indicates the overall diagnostic rate for this study (39.3 %). Fisher 
exact test used to determine statistical significance with *p < 0.05 and 
**p < 0.005
Table 1  Reported ethnic and phenotypic characteristics of patients 
evaluated in this study
Characteristic Number %
Sex
 Male 561 50.1
 Female 550 49.2
 NP 8 0.7
Age when ordered (years)
 Age ≤2 415 37.1
 Age 3–17 607 54.2
 Age ≥18 82 7.3
Ethnicity
 Caucasian 549 49.1
 Hispanic 128 11.4
 African American 51 4.6
 Asian 40 3.6
 Mixed ethnicity 57 5.1
 Middle Eastern 25 2.2
 Ashkenazi Jewish 8 0.7
 Other 7 0.6
 NP 254 22.7
Family history
 Autosomal recessive 226 20.2
 Autosomal dominant 141 12.6
 X-linked 1 0.1
 Ambiguous 8 0.7
 No family history 604 54.0
 NP 139 12.4
Onset
 Congenital 629 56.2
 Childhood 325 29.0
 Adult 18 1.6
 NP 147 13.1
Severity
 Normal 1 0.1
 Mild-moderate 306 27.3
 Severe-profound 399 35.7
 NP 413 36.9
Laterality
 Bilaterally symmetric 532 47.5
 Unilateral 69 6.2
 Asymmetric 92 8.2
 NP 426 38.1
Not SNHL
 Conductive 6 0.5
 Mixed 24 2.1
Physical exam
 Normal 683 61.0
 Any abnormality 233 20.8
 NP 203 18.1
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on 72 patients. For all other individuals, the available clini-
cal information was considered during Hearing Group 
Meeting and discussed in the context of the genetic data. 
The most common characteristics included: Caucasian eth-
nicity (49 %); young age (93 % were <18 years of age); 
congenital hearing loss (56 %); severe-to-profound hearing 
loss (36 %); and symmetric impairment (48 %). Patients 
most commonly had no family history of hearing loss 
(54 %) and a normal physical exam (61 %).
Genetic diagnoses
We identified a genetic cause of hearing loss in 440 patients 
(39 %) (Table S3). Of these patients, 101 (23 %) received a 
genetic diagnosis implicating an NSHL mimic, which included 
Usher syndrome (59 patients), Pendred syndrome (29 patients), 
Deafness-infertility syndrome (6 males and 1 female with 
NSHL), Alström syndrome (1 patient), autosomal dominant 
non-ocular Stickler syndrome (1 patient), branchiootorenal 
syndrome (BOR) (2 patients), MYH9-associated disease (1 
patient), and Wolfram syndrome (1 patient) (Table S4).
Panel versioning
During the course of this study, the TGE + MPS platform 
was updated from v4 to v5 as part of our standard operating 
procedure, increasing the number of genes screened from 
66 to 89. Of the 711 patients analyzed on v5, 11 patients 
carried causative variants in genes not included in v4, 
thus increasing the diagnostic rate by 2 % in all patients 
screened with V5 and accounting for 4 % of all positive 
diagnoses (11 of 263 positive diagnoses). Read metrics 
for V4 and V5 are shown in Table S5. Although patients 
sequenced with v5 had a lower average number of reads 
and lower average target coverage, the percentage of reads 
overlapping target was higher, as was the coverage at 1, 20, 
and 30×.
Variant identification
Our analysis of 1119 patients identified 5900 variants, 
which we reported to healthcare providers. 14 % of variants 
were considered causally related to the hearing loss pheno-
type and reported as pathogenic or likely pathogenic; 4 % 
were previously reported pathogenic variants for recessive 
hearing loss, with a second variant not identified (carrier 
status); and 82 % of variants were reported as VUSs. The 
median number of reported variants was 4 (range = 0–14) 
and 5 (0–19) for v4 and v5, respectively (Fig. S1).
Diagnostic rate and phenotype
There was considerable phenotypic diversity that impacted 
the overall diagnostic rate of 39 % (Fig. 1). In patients with 
a family history of dominant hearing loss, for example, the 
diagnostic rate was 50 % (p < 0.05), while in patients with 
a family history of recessive hearing loss it was only 41 % 
(not significant—n.s.). In patients with no family history of 
hearing loss, the diagnostic rate was 37 % (p < 0.05).
When age of onset is considered, patients with congeni-
tal hearing loss had a diagnostic rate of 44 %, which was 
significantly greater than the diagnostic rate in patients 
with childhood (29 %)- or adult (28 %)-onset hearing loss 
(p < 0.005 in both cases). Patients with bilateral hearing 
loss were significantly more likely to receive a diagnosis 
than patients with asymmetric or unilateral hearing loss 
(44, 22 and 1 %, respectively; p < 0.005). Patients with 
conductive or mixed hearing loss had a decreased likeli-
hood of receiving a genetic diagnosis (17 and 21 %, respec-
tively), but the difference was not significant.
Any kind of abnormality on physical exam decreased 
the likelihood of a genetic diagnosis using this panel (27 %, 
p < 0.005), as compared to patients with NSHL (42 %, n.s.). 
In patients with a clinical diagnosis of Usher or BOR syn-
dromes, the diagnostic rate was 31 and 37 %, respectively. In 
none of the 15 patients with neurological findings (seizures 
or severe mental retardation) and hearing loss was a non-
syndromic genetic cause for deafness identified (Table S6).
Combining demographic characteristics provided a 
more realistic assessment of the diagnostic rate (Figs. 1, 
2). Patients with dominant, recessive or no family history 
of hearing loss had diagnostic rates of 50, 41, and 37 %, 
respectively. If the hearing loss was also congenital, the 
diagnostic rate increased to 55, 43, and 44 %. Additional 
phenotypic characteristics further improved the diagnostic 
rate (Fig. S2). For example, a patient with a negative family 
history for hearing loss had a lower-than-average diagnostic 
rate (37 %); however, if the hearing loss was congenital, the 
diagnostic rate increased to 44 % (p < 0.005 as compared 
to patients with non-congenital hearing loss and a nega-
tive family history for hearing loss). With congenital onset 
and symmetric hearing loss, the rate increased to 48 % 
(p < 0.005), and if the physical examination was normal, 
it increased further to 51 % (p < 0.005). The same trend 
was true for patients with family histories of dominant and 
Table 1  continued
Characteristic Number %
Previous testing
 Any 147 13.1
 DFNB1 99 8.8
 DFNB1 and other genes 19 1.7
 Other genes 24 2.1
NP not provided, SNHL sensorineural hearing loss
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recessive hearing loss—their diagnostic rates jumped to 67 
and 55 %, respectively, when the hearing loss was congeni-
tal and symmetric and the physical examination was other-
wise normal.
For adult-onset hearing loss, the diagnostic rate was 28 %, 
however, if the family history was positive, the diagnostic 
rate climbed to 50 %, and if the patient also had symmetric 
hearing loss, the diagnostic rate jumped again to 67 %.
Only when the hearing loss was unilateral was there 
a marked negative impact on diagnostic rate (1 % of 
patients). This finding, when combined with any other 
characteristic, decreased diagnostic success (Fig. 2).
Diagnostic rate by ethnicity
Ethnic differences impacted the diagnostic rate (p < 0.005). 
In the cohort self-identified as Caucasian (549, 49 %), the 
diagnostic rate was 38 %. However, in cohorts self-identi-
fied as Asian (40, 4 %) and Middle Eastern (25, 2 %), the 
diagnostic rate was 63 and 72 %, respectively (p < 0.005). 
The diagnostic rate was lowest in African Americans (51, 
5 %), at 26 %, p < 0.05 (Fig. 3).
Genetic spectrum
In total, 49 genes were causally implicated in hearing loss 
(Table 2). However, nearly three-fourths of all diagnoses 
(317 of 440, 72 %) were attributable to 10 genes. The four 
genes most frequently implicated were GJB2 (22 %), STRC 
(16 %), SLC26A4, (7 %) and TECTA (5 %), although this 
list varied based on degree of hearing loss. For example, 
while variants in GJB2 were the most common cause of 
severe-to-profound hearing loss (20 %), STRC accounted 
for 30 % of diagnoses in persons with mild-to-moderate 
hearing loss, followed closely by GJB2 (25 %) and then 
TECTA (7 %). SLC26A4 pathogenic variants were identi-
fied in 7 % of patients with positive diagnoses; however, all 
of these patients had severe-to-profound hearing loss (10 % 
of severe-to-profound hearing loss).
Frequency of causative genes also varied by ethnicity 
(Fig. 3, S4). For example, amongst self-identified Cau-
casian and Hispanics, STRC-related deafness was just as 
likely to be diagnosed as GJB2-related deafness (21 vs. 
20 % and 16 vs. 14 %, respectively), but in Middle East-
ern or Asian patients, GJB2 diagnoses were more common 
than STRC diagnoses (17 vs. 6 % and 36 vs. 4 %, respec-
tively). No African American patients were diagnosed with 
GJB2-related hearing loss (Fig. 3, S4).
Causal variants
The profile of causal variant type differed with inherit-
ance pattern. Amongst all 440 diagnoses, 49 % were due to 
missense variants (Table S7); however, if the hearing loss 
was dominantly inherited, missense variants were diag-
nosed 85 % of the time, as compared to 46 % with reces-
sive inheritance. Variants predicting null alleles were much 
more common with recessive diagnoses—CNVs, indels, 
nonsense variants, and splice variants made up 20, 19, 9, 
and 6 % of recessive and 2, 3, 5, and 5 % of dominant diag-
noses. 146 CNV alleles in 9 different genes were identified 
as causative in 88 patients (GJB2, MYH9, OTOA, PCDH15, 
SLC26A4, STRC, TMC1, TMPRSS3, USH2A). These genes 
contributed to 20 % of all 440 diagnoses, including one 
dominant diagnosis.
Discussion
Amongst studies of genetic hearing loss, this report is 
unique as no restrictive criteria were imposed on patient 
selection. Comprehensive genetic testing was completed on 
1119 sequentially accrued and unrelated patients. Follow-
ing a collaborative diagnostic meeting (Hearing Group) at 
which identified genetic variants in each patient were dis-
cussed in the context of the patient-specific phenotype, a 
genetic cause of hearing loss was identified in 440 patients 
(39 %) (Table S3). Several smaller studies have reported 
similar diagnostic rates (Shearer and Smith 2015).
Our data show that a focused history and physical exam-
ination can guide the expected outcome when genetic test-
ing is ordered. The phenotypic correlations that improve or 
decrease the diagnostic utility of genetic testing are intui-
tive and logical. For example, we found that a family his-
tory positive for hearing loss improved diagnosis (44 % for 
dominant or recessive family history compared to 37 % for 
no family history).
Symmetry of hearing loss also impacted diagnosis. In 
patients with an otherwise normal physical exam, if the 
hearing loss was symmetric, the diagnostic rate was 48 %. 
However, a genetic cause was never identified in patients 
with ‘presumed’ unilateral NSHL suggesting that this con-
dition does not exist (Figs. 1, 2). In fact, the only instance 
of a positive genetic diagnosis associated with unilateral 
hearing loss was in a patient with a family history of BOR 
syndrome caused by a truncating variant in EYA1, a well-
recognized phenotype–genotype association (Chang et al. 
2004; Chen et al. 1995).
Ethnicity impacted diagnostic rate. Nearly half (49 %) 
of the patients in this study self-identified as Caucasian 
and had a diagnostic rate of 38 %. In patients of Middle 
Eastern ethnicity, the diagnostic rate was higher (72 %), 
an increase that reflects the higher coefficient of inbreed-
ing in this population (Najmabadi and Kahrizi 2014). Coef-
ficient of inbreeding is known to vary across populations, 
ranging from 0.0365 in Bedouins to 0.0026 in Japanese and 





































































































































































Male 561 281 69 23 16 11 2 25 3 58 123 299 326 153 9 154 194 258 52 38 2 11 333 117 43 11 21 50.1









AD 58 83 80 11 5 1 2 4 12 1 141 75 45 8 53 40 70 16 8 1 3 87 30 2 2 1 12.6
AR 123 101 113 35 11 6 8 2 16 3 226 147 65 2 68 93 123 18 15 2 0 160 45 25 8 6 20.2
No family history 299 305 305 70 30 26 12 2 29 3 604 372 197 7 165 243 309 50 43 2 17 399 140 64 6 23 54
Congenital 326 302 326 74 23 17 19 6 34 3 75 147 372 629 158 258 325 50 35 3 11 412 149 67 12 23 56.2
Childhood 153 172 161 39 23 12 5 2 21 4 45 65 197 325 122 117 163 35 27 2 10 220 64 28 7 8 29
Adult 9 9 14 1 0 0 0 0 0 0 8 2 7 18 5 9 11 2 1 0 0 14 3 0 0 0 1.6
Mild-moderate 154 151 170 32 10 13 4 4 21 3 53 68 165 158 122 5 306 208 52 14 4 15 201 71 29 5 6 27.3
Severe-profound 194 204 213 52 23 16 16 4 22 4 40 93 243 258 117 9 399 286 36 38 1 6 263 93 50 12 23 35.7
Symmetric 258 273 302 60 22 25 19 5 27 5 70 123 309 325 163 11 208 286 532 2 9 357 126 66 15 25 47.5
Asymmetric 52 40 50 12 5 3 0 1 5 2 16 18 50 50 35 2 52 36 92 1 9 54 26 8 2 1 6.2
Unilateral 38 31 36 9 7 1 0 1 6 0 8 15 43 35 27 1 14 38 69 2 6 45 13 4 1 2 8.2
Conductive 2 4 3 0 0 0 0 0 0 0 1 2 2 3 2 0 4 1 2 1 2 6 3 3 0 0 0 0.5
Mixed 11 13 15 2 0 1 0 0 0 0 3 0 17 11 10 0 15 6 9 9 6 24 10 8 3 1 1 2.1
Normal PE 333 349 350 86 32 26 19 8 42 5 87 160 399 412 220 14 201 263 357 54 45 3 10 683 66 15 13 61
Abnormal PE 117 116 128 25 10 13 3 0 10 2 30 45 140 149 64 3 71 93 126 26 13 3 8 233 20 3 19 20.8
DFNB1 43 56 57 11 2 5 1 2 7 0 2 25 64 67 28 0 29 50 66 8 4 0 3 66 20 99 4 8.8
DFNB1 & other 11 8 10 3 1 2 1 0 1 0 2 8 6 12 7 0 5 12 15 2 1 0 1 15 3 19 1 1.7
Other testing 21 13 21 6 1 2 0 0 0 0 1 6 23 23 8 0 6 23 25 1 2 0 1 13 19 4 1 34 2.1































































































































































Male 38.7 37.0 37.7 26.1 81.3 45.5 32.0 55.2 36.6 36.5 43.3 28.1 38.3 34.5 44.2 19.2 0.0 0.0 40.5 30.8 34.9 63.6 23.8










AR 36.6 44.6 44.2 25.7 27.3 37.5 40.7 42.9 32.3 50.0 33.3 45.5 22.2 0.0 45.0 15.6 48.0
No family history 36.5 36.7 34.1 34.3 26.7 53.8 75.0 37.9 36.6 43.5 26.4 38.2 34.6 42.1 22.0 0.0 17.6 38.6 30.0 40.6 21.7
Congenital 43.3 45.0 40.8 39.2 39.1 76.5 73.7 47.1 54.7 42.9 43.5 44.2 47.5 39.9 49.2 24.0 2.9 18.2 46.8 30.9 44.8 58.3 30.4
Childhood 28.1 30.2 31.7 23.1 13.0 58.3 28.6 37.8 32.3 26.4 29.2 35.2 25.6 34.4 20.0 0.0 20.0 32.3 21.9 32.1
Adult 35.7 7.534.638.72
Mild-moderate 38.3 45.0 44.1 43.8 30.0 61.5 47.6 49.1 50.0 38.2 47.5 35.2 41.8 49.5 19.2 0.0 13.3 49.8 22.5 48.3






Normal PE 40.5 42.4 40.0 34.9 37.5 69.2 73.7 42.9 50.6 45.0 38.6 46.8 32.3 35.7 49.8 34.2 47.6 27.8 0.0 20.0 41.6 45.5 40.0 15.4
Abnormal PE 30.8 24.1 27.3 20.0 10.0 46.2 30.0 33.3 15.6 30.0 30.9 21.9 22.5 30.1 31.0 11.5 7.7 27.5 25.0 15.8
DFNB1 4.040.525.544.240.833.841.238.446.040.845.546.836.449.43
DFNB1 & other 4.740.047.640.053.850.046.36
Other testing 6.028.514.510.027.124.037.120.914.518.32
0 10 20 30 40 50 60 70 80 90 100
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5.96E−8 in an Afro-European admixed population of Chi-
cago (Pemberton and Rosenberg 2014).
That the diagnostic rate was lowest in African Ameri-
cans and the ‘Other’ group (which included patients of 
African, Bahaman or Native American heritage) suggests 
that there is a ‘discovery gap’ to fill in these ethnic groups 
(Gasmelseed et al. 2004; Shan et al. 2010). Nevertheless, 
in all ethnic groups, a relatively large number of less fre-
quently implicated genes accounted for 10–15 % of diag-
noses (Fig. 3), implying that across populations a similar 
proportion of hearing loss is due to multiple, rare, ethnic-
specific variants that arise randomly and independently.
In many of the world’s populations, variants in GJB2 
are the predominant cause of congenital severe-to-pro-
found ARNSHL (Kenneson et al. 2002). In this study, 
they accounted for 22 % of all diagnoses and 26 % of 
diagnoses in the congenital severe-to-profound ARNSHL 
cohort. The ethnic-specific breakdown of GJB2-related 
hearing loss in Caucasian, Hispanic, African American, 
Asian, and Middle Eastern patients was 20, 14, 0, 36 and 
17 %, respectively (Fig. 3, S2). When corrected for GJB2 
pre-screening, the percentages increased slightly (22, 16, 
0, 45, and 17 %, respectively), which is in agreement with 
other reports (Bazazzadegan et al. 2012; Dai et al. 2009; 
Du et al. 2014; Pandya et al. 2003; Usami et al. 2012).
STRC causative variants accounted for 30 % of diagno-
ses in patients with mild-moderate hearing loss, providing 
the most common diagnosis among those with this degree 
of hearing loss. In aggregate, 16 % of diagnoses impli-
cated STRC. It is noteworthy that the majority of causative 
mutations in STRC involved large CNVs (99 %), under-
scoring the requirement that all comprehensive genetic 
testing panels for hearing loss include CNV detection.
Of variants with a MAF of <0.01, the largest majority 
were of unknown significance (VUSs, Fig. S1). In addition, 
however, we identified several known or likely pathogenic 
variants associated with ARNSHL in genes without a sec-
ond causal variant. For example, 151 of the 679 patients, in 
whom a genetic diagnosis was not made, carried reported 
ARNSHL-causal variants without having a second vari-
ant in the coding sequence of that gene. This carrier rate of 
22 % is roughly 8 times higher than that reported in hear-
ing control populations and suggests that many of these 
patients have yet-to-be-identified non-coding mutations 
(Green et al. 1999).
Variant annotation is a dynamic process. Interpreta-
tion of variants as pathogenic, likely pathogenic, VUS, 
likely benign and benign is continuously refined based on 
increasingly robust data. The Deafness Variation Data-
base (deafnessvariationdatabase.org) captures this area 
of active study in an open-source, continuously updated, 
interpretational database that we maintain on all variant 
positions interrogated on the OtoSCOPE platform.
In summary, we believe that comprehensive genetic 
testing is a foundational diagnostic test that allows 
healthcare providers to make evidence-based decisions 
in the evaluation of hearing loss thereby providing bet-
ter and more cost-effective patient care (Fig. 4, Table S8). 
While only 10 genes accounted for 72 % of diagnoses, 
49 genes were identified as causative and 20 % of diag-
noses involved at least one CNV (Table 2 and Shearer 
et al. (2014b)), mandating comprehensive TGE + MPS 
and thorough data analysis. While whole exome sequenc-
ing (WES) is becoming cheaper and for many indications 
more practical, a focused deafness-specific panel contin-
ues to offer the advantages of better coverage of targeted 
regions, greater facility to detect multiple variant types 
(including CNVs and complicated genomic rearrange-
ments), substantially lower costs, higher throughput, sim-
pler bioinformatics analysis, and focused testing, obviat-
ing the need to deal with secondary/incidental findings that 









































































































Fig. 3  Solve rate and implicated genes across ethnicities. The 10 
genes with ≥10 diagnosis for the entire cohort are plotted individu-
ally; all other genes diagnosed are grouped as “other”. Ethnic-specific 
differences are readily apparent
Fig. 2  Diagnostic rate is influenced by ethnic, clinical and pheno-
typic characteristics. a N for each combination of two reported char-
acteristics for all combinations. Color/shading reflects the number 
of patients with the paired criteria, up to the maximum of n = 683. 
b Diagnostic success for each corresponding category in a. Color-
ing/shading indicative of diagnosis: light orange indicates below 
average diagnostic rate, yellow indicates close to average diagnos-
tic rate (39.3 %), and dark green indicates above average diagnostic 
rate. Empty squares had fewer than 10 individuals. AD autosomal 
dominant, AR autosomal recessive, PE physical exam, DFNB1 prior 
genetic DFNB1 (GJB2) testing, DFNB1 & other prior genetic testing 
including DFNB1 and other tests, other testing prior genetic testing 
excluding DFNB1 testing
◂
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Table 2  Diagnoses and 
inheritance patterns in 440 
patients with genetic hearing 
loss
Gene Total diagnoses Autosomal dominant Autosomal recessive Mitochondrial or 
X-linked
Diagnoses % Diagnoses % Diagnoses % Diagnoses %
GJB2 95 21.6 1 1.6 94 25.3
STRC 71 16.1 71 19.1
SLC26A4 29 6.6 29 7.8
TECTA 23 5.2 15 23.8 8 2.2
MYO15A 21 4.8 21 5.6
MYO7A 20 4.5 1 1.6 19 5.1
USH2A 19 4.3 19 5.1
CDH23 18 4.1 18 4.8
ADCRV1 12 2.7 12 3.2
TMC1 10 2.3 2 3.2 8 2.2
PCDH15 9 2.0 9 2.4
OTOF 9 2.4
TMPRSS3 9 2.4
LOXHD1 8 1.8 8 2.2
OTOA 8 2.2
WFS1 7 1.6 5 7.9 2 0.5
COL11A2 6 1.4 5 7.9 1 0.3
KCNQ4 6 9.5
MYH14 5 1.1 5 7.9
MYO6 4 6.3 1 0.3
ACTG1 4 0.9 4 6.3
PTPRQ 4 1.1
MYH9 3 0.7 3 4.8
OTOGL 3 0.8
TRIOBP 3 0.8







TPRN 1 1.6 1 0.3
WHRN 2 0.5
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